Hematopoietic chimerism as a predictive marker for the relapse of acute leukemia after allogeneic BMT was evaluated in a prospective study. Monthly assays of hematopoietic chimerism were performed from peripheral blood samples by PCR amplification of short tandem repeats or amelogenin loci. Between December 1997 and June 1999, 33 patients enrolled and 30 were evaluable (two early deaths, one lack of informative bands for chimerism evaluation). There were 14 male and 16 female patients (15 AML and 15 ALL) with a median age of 31 years (range 16-46). Mixed chimerism (MC) was observed at least once in 14 of 30 patients (47%). There was no significant difference between 14 patients who showed MC (MC group) and 16 patients who did not show MC (complete chimerism (CC) group) in terms of age, sex, disease status at BMT, donor type, and the number of bone marrow cells infused. There was no significant difference in the neutrophil and platelet engraftment rates between the two groups. After a median follow up of 10.9 months (range 4.3-22.4), five patients in the CC group and two patients in the MC group relapsed (P = 0.27). All five patients who relapsed in the CC group maintained CC up to 1 month prior to clinical relapse. Our study demonstrated that the patients who showed MC post BMT did not have higher risk of relapse of acute leukemia when compared to patients who did not show MC. Sensitive PCR-based assays for hematopoietic chimerism applied on a monthly basis after allogeneic BMT could not predict relapse of acute leukemia. Bone Marrow Transplantation (2000) 26, 327-332. Keywords: acute leukemia; allogeneic bone marrow transplantation; mixed chimerism; relapse It is now well established that a certain proportion of patients who undergo myeloablative chemoradiotherapy and allogeneic bone marrow transplantation (BMT) show
evidence of recovery of recipient hematopoiesis after BMT. [1] [2] [3] [4] [5] [6] [7] [8] Such mixed chimerism (MC) in the hematopoietic system was suggested to be a marker of immune tolerance as well as closer tissue matching between the donor and recipient on the basis of a decreased incidence of graftversus-host disease (GVHD). [1] [2] [3] [4] [5] Several studies suggested that MC after allogeneic BMT may correlate with relapse in chronic myelogenous leukemia (CML). [4] [5] [6] [7] [8] These studies showed that increasing proportions of recipient cells over time are highly associated with subsequent relapse while low levels of persisting recipient cells are not associated with an increased risk of relapse. In cases of acute leukemia, however, the significance of MC as a predictive marker for relapse is less clear. There are several studies which suggest a correlation between increasing levels of recipient cells and relapse in acute leukemia [9] [10] [11] while others found no such correlation. 4, 8, 12, 13 This study was undertaken to investigate whether we could predict relapse of acute leukemia after allogeneic BMT by evaluation of hematopoietic chimerism at regular intervals. Monthly serial analyses of hematopoietic chimerism were performed in patients with acute leukemia after allogeneic BMT using PCR amplification of short tandem repeats (STRs) or amelogenin loci.
Patients and methods

Patients
Consecutive patients with acute leukemia who underwent allogeneic BMT at Asan Medical Center, Seoul, Korea were enrolled in the study. Detailed transplantation procedures are described elsewhere. 14, 15 All patients received the BuCy regimen (busulfan 4 mg/kg/day on days −7 to −4 and cyclophosphamide 60 mg/kg/day on days −3 to −2) for conditioning therapy. Donor marrow cells were not T cell depleted. The regimen for the prophylaxis of GVHD consisted of cyclosporine (1.5 mg/kg intravenously every 12 h starting on day −1) combined with a short course of methotrexate (15 mg/m 2 intravenously on day 1, then 10 mg/m 2 on days 3, 6 and 11). Anti-thymocyte globulin or anti-lymphocyte globulin were not used. Cyclosporine was switched to an oral dose of four times the intravenous dose when oral intake became feasible. If there was no evidence of GVHD, the cyclosporine dose was tapered by 10% each month starting on day 60.
Specimens
Peripheral blood samples were obtained from the donor and the recipient before BMT. After BMT, recipient peripheral blood samples were drawn monthly for the first 12 months and then every 3 months for an additional 2 years or until death. Fresh peripheral blood mononuclear cells were isolated by Ficoll-Hypaque density sedimentation. Genomic DNA was extracted from isolated mononuclear cells using the Wizard Genomic DNA purification Kit (Promega, Madison, WI, USA).
PCR analysis
STRs are di-, tri-, tetra-or penta-nucleotide repeat sequences that are widely dispersed throughout the human genome. These loci show Mendelian inheritance and represent useful markers for individual identification. 16 The length of PCR-amplified fragment is directly proportional to the number of repeat units present, thus allowing the identification of different individuals . A panel of nine  paired primers for STR loci including CSF1PO,   17   F13A01,  17 FESFPS,  17 LPL,  17 TPOX,  18 TH01,  19 HPRTB,   19 vWA, 20 and F13B 21 (GenePrint STR Systems; Promega) was used in the initial screening process to identify the most informative STR locus in a given donor/recipient pair. An STR locus was defined as being informative for a given donor/recipient pair if there was at least one unique band of the recipient that could be distinguished from the band(s) of donor. When possible, the STR locus in which at least one recipient-specific allele had a longer PCR-amplified fragment than those of donor alleles was chosen to avoid misinterpretation of results by artifacts of donor alleles. These artifacts are commonly generated and usually located at one or two repeat units below the original bands by the mechanism known as slipped mispairing in PCR amplification of STRs. 22 If an artifactual band from the donor is in the same position as the recipient's unique band, then the interpretation of the result could be compromised. When there was no usable locus in the STR system, the amelogenin system was chosen in cases where the recipient was male and the donor was female. Amelogenin displays a 212 base X-specific band and a 218 base Y-specific band, thus allowing discrimination between X and Y-chromosomes. 23 After screening, PCR analyses were carried out on sequential post-transplant samples of the recipient using the most informative locus for each donor/recipient pair. All reactions were performed in a volume of 25 l containing 50 mmol/l KCl, 10 mmol/l Tris-HCl (pH 9.0), 1.5 mmol/l MgCl 2 , 0.1% Triton X-100, 200 mol/l of each dNTP, 2.5 l of each 10× primer pair (Gene Print STR Systems; Promega), 0.5 U of Taq polymerase (Promega), and 250 ng of template DNA. Following amplification, PCR products were electrophoresed on a 6% polyacrylamide gel containing 7 m urea and 0.5× TBE. For loading, 2.5 l of each PCR product was mixed with an equal volume of formamide loading buffer containing xylene cyanol. Before loading the samples, the gel was pre-run at 40 watts for 30 min to achieve a gel surface temperature of approximately 50°C. After denaturing at 95°C for 2 min, 3 l of the each sample was loaded on the respective well and electrophoresed at 40 watts until the xylene cyanol dye reached the end of plate. Following electrophoresis, silver staining was done for direct visualization. 24 If there was MC, signals of each band were analyzed densitometrically using GelDoc 1000 imaging system and Multi-Analyst/PC software (Bio-Rad, Hercules, CA, USA) for quantification of the degree of MC. The degree of MC was defined as the proportion of recipient cells in a given sample and determined by the proportion of the peak areas corresponding to recipient signals as compared to the sum of peak areas of the donor and recipient signals as described by Thiede et al. 25 The value was rounded off to the nearest 5%.
Definition of mixed chimerism
MC was defined as coexistence of both recipient and donor hematopoietic cells after allogeneic BMT. Complete donor chimerism (CC) was defined as the presence of only donor type hematopoietic cells after allogeneic BMT. Coexistence of both recipient and donor cells at the time of relapse was not considered as MC to exclude patients whose recipient cells reflect leukemic cells instead of normal hematopoietic cells. The patients were divided into two groups based on their post-transplant hematopoietic chimerism. Patients who exhibited complete donor hematopoiesis at all times were defined as the CC group. Patients who demonstrated the MC on one or more occasions at any time until last followup were defined as the MC group.
Statistics and data analysis
Categorical variables were compared using Fisher's exact test or chi-square test for trend. Continuous variables were compared using Student's t-test after log conversion. Time to leukemia relapse and overall survival (OS) were measured from the time of BMT. The cumulative incidence of leukemia relapse and survival were compared using log-rank test.
Results
Clinical characteristics of patients
Between December 1997 and August 1999, 33 patients with acute leukemia underwent T cell non-depleted allogeneic BMT. Two patients died of transplantation-associated complications within 1 month after BMT before they could be evaluated for chimerism. In one patient/donor pair, an informative band for chimerism analysis could not be identified due to slippage artifact bands which hampered evaluation of the recipient band. Thus, 30 patients were evaluable for the analysis of post-transplant hematopoietic chimerism. The clinical data of 30 evaluable patients are presented in Table 1 . The median age of the patients was 31 years (range 16-46) with 14 male and 16 female patients. There were 15 patients with AML and 15 with ALL. Twenty-four patients were in first CR and five were in second CR at the time of BMT. Twenty-three patients received marrow from HLA-matched siblings and seven received from HLA-matched unrelated donors.
Sensitivity of the assay
To assess the sensitivity level of each primer pair used to detect a minor cell population, mixing experiments were performed. Donor and recipient DNAs were mixed in different proportions (R/D ratio = 50:50, 25:75, 10:90, 5:95, 2.5:97.5, 1:99 and 0.5:99.5) keeping the total amount of DNA constant at 250 ng. The sensitivity was determined as the lowest concentration of DNA that produced a visible specific STR band for minor cell population. The sensitivity to detect a minor cell population with the STR-PCR assay was in the range of 0.5-2.5% depending on the primers used. The amelogenin system detected a minor cell population at the 0.5% level. Further dilution experiments below 0.5% level were not done.
Frequency of mixed chimerism
The frequency of MC was 43% (13/30), 28% (8/29), 27% (7/26), 22% (5/23), 23% (5/22) and 5% (1/20) at 1, 2, 3, 4, 5 and 6 months post BMT, respectively. The frequencies of MC decreased over time. MC was observed at least once in 14/30 patients (47%) during the study period.
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Post-transplant chimerism status and clinical characteristics of patients
When we compared clinical characteristics of those patients who did not show MC during the study period (CC group) and those who showed MC (MC group), no significant difference was observed in terms of age, sex, diagnosis of AML vs ALL, disease status at the time of BMT, type of donors, and the amount of bone marrow cells infused (Table 2 ). There was no significant difference in the rates of neutrophil and platelet engraftment after BMT between the two groups. Median days to ANC over 500/l for 2 consecutive days were 16 in both groups (P = 0.88, Table 2 ). Median days to unsupported platelet count over 20 000/l for 7 consecutive days were 29 days in the CC group and 25 days in the MC group (P = 0.52, Table 2 ). (Figure 1b) . Her chimerism status returned to CC at 4 months, but multiple cutaneous relapses were documented at 5 months without evidence of disease in the bone marrow. The chimerism status at the time of cutaneous relapse was CC. She maintained CC until 6 months post BMT, but relapse was documented Table 3 Results of assays of hematopoietic chimerism and clinical outcome a The numbers in bold are the proportions of recipient cell population. b Denotes occurrence of death without relapse of leukemia. c Denotes occurrence of leukemia relapse. UPN = unique patient number; mo = months post transplant; MC = mixed chimerism; CC = complete donor chimerism; ND = assay not done; NED = no evidence of disease; aGVHD = acute GVHD; VOD = hepatic veno-occlusive disease.
eventually in the bone marrow at 7 months. In UPN 83, the degree of MC was 25% at 1 month post BMT and the level steadily decreased until 4 months to 5% (Figure 1c) . However, it began to rise rapidly from 5 months and he eventually relapsed at 6.5 months. Eleven patients in the MC group (UPNs 61, 63, 72, 74, 77, 79, 85, 87, 93, 95 and 110) who showed MC at 1 month post BMT eventually converted to CC at 2 to 6 months post BMT. Among these 11 patients, 10 were alive in complete remission at 4.3 to 22.4 months post BMT. One patient (UPN 95) died at 3.3 months post BMT due to acute GVHD. The remaining patient (UPN 55) in the MC group who showed low level MC for 2 consecutive months expired at 3 months post BMT due to hepatic venoocclusive disease. Overall, eight of 16 patients in the CC group and three of 14 patients in the MC group died and the difference was not statistically significant (P = 0.22, Table 2 ).
Chimerism and GVHD
In the CC group, four patients developed acute GVHD including one patient with grade I GVHD and three patients with grades II to IV GVHD. In the MC group, one patient who underwent HLA-matched unrelated donor transplantation developed grade IV acute GVHD. None of the other patients developed acute GVHD. Although the incidence of acute GVHD was higher in the CC group than in the MC group, the difference was not statistically significant (P = 0.34, Table 2 ).
Five of 16 patients in the CC group and four of 14 patients in the MC group developed chronic GVHD. Three of five patients in the CC group developed extensive disBone Marrow Transplantation ease while only one of four patients developed extensive disease in the MC group (Table 2) .
Discussion
The purpose of our study was to investigate in a prospective manner whether the relapse of acute leukemia after allogeneic BMT could be predicted when a sensitive PCR-based assay for hematopoietic chimerism was applied on a monthly basis. Our study showed that leukemia relapse could not be predicted reliably. Relapse rate of patients who showed MC post BMT (2/14) was not higher than that of patients who showed CC (5/16). Furthermore, six of seven patients who relapsed did so without showing an increasing degree of MC prior to clinical relapse.
The potential prognostic value of MC rests on the concept that MC indicates immune tolerance of the donor graft toward normal host tissues (decreased GVH reaction) as well as leukemic cells (decreased GVL reaction). [1] [2] [3] [4] [5] In contrast to cases with CML, where MC is felt to be a reliable marker for prediction of relapse after allogeneic BMT, 5-8 the prognostic significance of MC in acute leukemia after allogeneic BMT remains controversial. In cases with acute leukemia, there have been reports which suggest a high correlation between MC and relapse 9-11 while others found no such correlation. 4, 8, 12, 13 Bertheas et al 4 studied cytogenetic findings of 45 patients with acute leukemia and 15 patients with CML and showed that MC was associated with relapses in CML but not with relapses in acute leukemia. In patients with acute leukemia, six of 22 patients with CC and two of 22 patients with MC relapsed. Molloy et al 13 studied the correlation between MC and relapse in 28 patients with ALL who received T cell-depleted allograft from unrelated donors. They found no correlation between increasing MC and relapse. Only five out of 12 patients with increasing MC relapsed in spite of long-term follow-up. The other seven patients remained in complete remission for a median of 30 months post BMT. In a study by Serrano et al, 8 two out of four patients with acute leukemia who had increasing MC relapsed. The other two patients were in continuous remission at 3 and 4 years, respectively.
In contrast to the above studies, Bader et al 10 stated that relapse of acute leukemia could be predicted using a PCRbased assay for variable number of tandem repeats of DNA. In their study, the assays were performed weekly after engraftment until discharge from the hospital then monthly for 18 months. If MC was detected, the monitoring was intensified by analyzing patient samples twice a week. Of 55 patients studied, 18 showed MC. Of 18 patients with MC, 10 patients showed increasing MC and nine of those patients eventually relapsed. In some of such cases, MC may be due to the emergence of leukemic cells rather than due to the normal hematopoietic cells of recipient origin.
In our study, when sensitive PCR-based assays were used prospectively on a monthly basis, six (UPN 59, 60, 62, 67, 71 and 73) of seven patients relapsed without either prior detection or an increasing level of MC (Table 3) . Our findings are consistent with those of Suttorp et al 12 who showed that seven of eight patients with acute leukemia who relapsed after allogeneic BMT did not show MC before relapse in spite of the fact that sensitive DNA-RFLP assays had been performed shortly (30-86 days) before clinical relapse. It may be stated that these patients relapsed without increased immune tolerance of the donor allograft toward the normal recipient hematopoietic cells.
For the detection of an emerging leukemic clone before clinically documented relapse, assays for MC may need to be performed more frequently than once a month. The effectiveness of such an approach needs to be investigated further.
Although no clear conclusion could be made due to the limited number of patients in our study, there was no significant correlation between the development of MC and patient age, sex, diagnosis of AML vs ALL, the disease status at the time of BMT, type of bone marrow donor, and the number of bone marrow cells infused. Patients with MC showed a trend toward decreased incidence and severity of GVHD. Further studies are needed to define the risk factors for the development of MC after allogeneic BMT. A clinically meaningful definition of MC needs to be investigated as well.
In conclusion, our study showed that the relapse of acute leukemia could not be predicted reliably from monthly serial assays of hematopoietic chimerism following allogeneic BMT. Complete donor chimerism could not rule out the risk of relapse. Further well-designed prospective studies in a larger number of patients are necessary for a clear understanding of the dynamic relationship between chimerism and relapse of acute leukemia after allogeneic BMT.
